Analysis of clinical characteristics and outcomes of ALK positive (ALK plus ) patients treated with ALK inhibitors (ALKi).

被引：0

作者：

Perez, Susana Cedres

Aranda, Nuria Pardo

Navarro, Alejandro

Marti, Alex Martinez

de Castro, Ana Maria Martinez

Cabrera, Guadalupe

Vilaro, Marta

Carbonell, LLuisa

de la Fuente, Iris

Piera, Adelaida

Martinez, Lidia

Hernandez-Losa, Javier

Sansano, Irene

Felip, Enriqueta

机构：

[1] Vall dHebron Univ Hosp, Barcelona, Spain

[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain

[3] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[4] Inst Salvadoreno Seguro Social, San Salvador, El Salvador

[5] Vall dHebron Inst Oncol, Oncol Data Sci OdysSey Grp, Barcelona, Spain

[6] Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain

[7] Vall dHebron Univ, Barcelona, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.e20550

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e20550

引用

页数：2

共 50 条

[21] Clinical Outcomes and ALK Resistance Mutations in ALK plus Non-Small Cell Lung Cancer According to EML4-ALK Variant
Lin, J.
Zhu, V.
Yoda, S.
Yeap, B.
Jessop, N.
Schrock, A.
Dagogo-Jack, I.
Gowen, K.
Stephens, P. J.
Ross, J.
Ali, S.
Miller, V.
Gainor, J.
Hata, A.
Iafrate, A.
Ou, S.
Shaw, A.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1828 - S1828
[22] Analysis of ALK Status in Peripheral Blood to Predict the Clinical Activity of Alk Inhibitors and Assess Prognosis in Patients with Lung Cancer
Zhou, Zhen
Zhang, Zhenzhen
Xu, Cheng
Ye, Yun
Yao, Yaxian
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1166 - S1166
[23] Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma
Redaelli, Sara
Ceccon, Monica
Pirola, Alessandra
Peronaci, Marco
Gambacorti-Passerini, Carlo
Mologni, Luca
BLOOD, 2015, 126 (23)
[24] Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
Redaelli, Sara
Ceccon, Monica
Antolini, Laura
Rigolio, Roberta
Pirola, Alessandra
Peronaci, Marco
Gambacorti-Passerini, Carlo
Mologni, Luca
ONCOTARGET, 2016, 7 (45) : 72886 - 72897
[25] Efficacy analysis of ALK inhibitors for treating lung squamous carcinoma patients harboring ALK rearrangement
Wei, Jingwen
Sun, Wei
Zeng, Xiaohong
Zhou, Huan
Song, Zhengbo
JOURNAL OF THORACIC DISEASE, 2024, 16 (07) : 4146 - 4154
[26] Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
Yoda, Satoshi
Lin, Jessica J.
Lawrence, Michael S.
Burke, Benjamin J.
Friboulet, Luc
Langenbucher, Adam
Dardaei, Leila
Prutisto-Chang, Kylie
Dagogo-Jack, Ibiayi
Timofeevski, Sergei
Hubbeling, Harper
Gainor, Justin F.
Ferris, Lorin A.
Riley, Amanda K.
Kattermann, Krystina E.
Timonina, Daria
Heist, Rebecca S.
Iafrate, A. John
Benes, Cyril H.
Lennerz, Jochen K.
Mino-Kenudson, Mari
Engelman, Jeffrey A.
Johnson, Ted W.
Hata, Aaron N.
Shaw, Alice T.
CANCER DISCOVERY, 2018, 8 (06) : 714 - 729
[27] Profound and Sustained Response with ALK Inhibitors in Patients with CNS Relapse or Progressive ALK- Positive Anaplastic Lymphoma
Rigaud, C.
Abbas, R.
Simonin, M.
Le Mouel, L.
Peraira, V.
Minard-Colin, V.
Geoerger, B.
Brugieres, L.
PEDIATRIC BLOOD & CANCER, 2019, 66 : S267 - S268
[28] Clinical Outcomes and Pathological Characteristics of Resected ALK plus Lung Adenocarcinoma: A Single Center Retrospective Analysis
Zou, Z.
Li, Y.
Xing, P.
Ying, J.
Li, J.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S986 - S986
[29] Integrated analysis of the clinical consequence and associated gene expression of ALK in ALK-positive human cancers
Saifullah
Tsukahara, Toshifumi
HELIYON, 2022, 8 (07)
[30] ALK-positive anaplastic large cell lymphoma (ALK plus ALCL): comprehensive diagnosis
Prouzova, Z.
Mrhalova, M.
Kabickova, E.
Kodet, R.
Kalinova, M.
VIRCHOWS ARCHIV, 2024, 485 : S99 - S100

← 1 2 3 4 5 →